Archive: May 2023

Blastic Plasmacytoid Dendritic Cell Neoplasm: Emerging Developments and Special Considerations for 2023

Abstract: The field of blastic plasmacytoid dendritic cell neoplasm (BPDCN) is rapidly evolving. Recent clinical developments in this ultra-rare hematologic malignancy have included the emergence of […]

Novel Approaches to the Treatment of Multiple Myeloma

Abstract: The treatment landscape for multiple myeloma (MM) has evolved significantly over the last decade with the approval of novel therapies and combinations in the newly […]

Management of Antithrombin Deficiency

H&O  What is antithrombin deficiency? IP  Antithrombin deficiency refers to a decrease in the natural clotting inhibitor, antithrombin. Antithrombin is important because it inhibits clotting factors, […]

The Emerging Use of Antibody-Drug Conjugates in Ovarian Cancer

H&O  Which patients with ovarian cancer are eligible for treatment with an antibody-drug conjugate (ADC)? DR  The only ADC that has received US Food and Drug […]

Letter From the Editor: How Do We Celebrate—and Survive—Increasing Survival?

As I approach my 25th year in oncology practice, I think back to when I started and the remarkable expansion since then of treatment options for […]

Dosing of Nivolumab in India

H&O  What factors determine the appropriate dose of nivolumab?  VN  The dosing of any drug is determined by multiple factors. Traditionally, drug dosing is initially determined […]

Quizartinib, the Next FLT3 Inhibitor

H&O  What are FMS-like tyrosine kinase 3 (FLT3) inhibitors, and how have they affected the treatment of patients with acute myeloid leukemia (AML)? JC  FLT3 mutations […]

Back to Archive